2012 the pharmaceutical industry- a competitive advantage is king.docVIP

2012 the pharmaceutical industry- a competitive advantage is king.doc

  1. 1、本文档共5页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  5. 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  6. 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  7. 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  8. 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
2012 the pharmaceutical industry- a competitive advantage is king

 PAGE \* MERGEFORMAT 5 2012 the pharmaceutical industry: a competitive advantage is king Look at the basis of China’s pharmaceutical industry face the situation in 2011: January to August 2011, cumulative production of chemical raw materials of the country over the previous year increased by 24.35% over the previous year’s growth rate rose 4.12 percentage points month in August than in the national production of chemical raw materials to reduce production in July of 40,900 tons, the chain growth -16.25% in July. medicine’s cumulative production up 32.48% over the previous year, an increase year on year increase of 9.59 percentage points, the development of better, but the month of August, down by proprietary production 1.96 million tons, production chain growth -9.39% in July. I believe that SHI Li-chen, on the whole, China’s pharmaceutical industry is still the pace of development in accordance with the established development, but we can analyze the fundamentals of composition, according to the relevant data: 1 the competitive advantage of API in the world market level is rapidly reduced (2) most of our production capacity and products of chemical drugs are generic basic 3 Although the gradual increase in the proportion of Chinese medicine, but a relatively small base 4 Most of the data is GuoZiHao business, deteriorating living environment for SMEs 5 The data base is in the low-end competition in the pharmaceutical products, high-end products basically monopolized imports The current competitive landscape of China’s pharmaceutical industry is low-level redundant construction, manufacturers everywhere, vicious competition, price wars dominate the market, low-cost generic drugs and medicine into the mainstream, market disorder, pharmaceutical companies within the industry to survive hard in vain. Normalized low-cost competition, will be a long-term future of China’s pharmaceutical industry in the normal period of time, because of China’s pha

您可能关注的文档

文档评论(0)

jiupshaieuk12 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

版权声明书
用户编号:6212135231000003

1亿VIP精品文档

相关文档